A case of ALS-FTD in a large FALS pedigree with a K17I ANG mutation. by Es, M.A. van et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/81626
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
Clinical/Scientific
Notes
M.A. van Es, MD
F.P. Diekstra, MD
J.H. Veldink, MD, PhD
F. Baas, PhD
P.R. Bourque, MD
H.J. Schelhaas,MD, PhD
E. Strengman
E.A.M. Hennekam, PhD
D. Lindhout, MD, PhD
R.A. Ophoff, PhD
L.H. van den Berg, MD,
PhD
A CASE OF ALS-FTD IN A LARGE FALS PEDIGREE
WITHAK17IANGMUTATION
Approximately 90% of amyotrophic lateral sclero-
sis (ALS) cases are sporadic (SALS), but 10% are
familial (FALS). Mutations in SOD1, Alsin, Dyn-
actin, SETX, DJ-1, VAPB, and TDP-431 have been
reported (table e-1 on the Neurology® Web site at
www.neurology.org). After the identification of
sequence variation VEGF in patients with ALS,
mutations in another angiogenic gene (ANG) were
identified in SALS and FALS.2,3 Studies in other
populations have identified ANG mutations in pa-
tients with ALS, but also in healthy controls. This
suggests that not all mutations are pathogenic.3,4
Methods. A total of 39 unrelated FALS patients,
negative for SOD1 mutations, were screened for
ANG mutations. This study was approved by the
local ethics committee and participants provided
informed consent. DNA was isolated from venous
blood and ANG mutation analysis was performed
as described in appendix e-1. A total of 275 unre-
lated, healthy controls were taken from a prospec-
tive population-based study on ALS in The
Netherlands and were also screened.5 PMut
(http://mmb2.pcb.ub.es:8080/PMut/) was used to
predict the impact of an amino acid substitution
on the structure and function of the protein.
Results. We identified one mutation in one pa-
tient (122 AT) (figure, A), leading to an amino
acid substitution of lysine to isoleucine (K17I)
(figure, B). PMut analysis predicted this mutation
to be pathogenic. Sequence alignments of ANG in
different species demonstrated high conservation
(figure, C).
Analysis of this pedigree revealed an autosomal
dominant inheritance of the mutation (male to
male transmission) (figure, D). DNA was available
from 44 out of 62 family members (five affected
individuals). All affected family members carried
the K17I mutation.
Ten carriers were identified, but all were under 50
years of age (except one who was 75 years old with-
out symptoms or signs of ALS). The K17I mutation
was not found in 275 control samples.
Cases III-3, III-4, and IV-1 all presented with
progressive upper and lower motor neuron loss of
limbs. Case III-1 rapidly developed weakness in both
arms with atrophy, fasciculations, and dyspnea, but
no upper motor neuron signs. The patient died after
6 months from onset. Case III-2 initially presented
with parkinsonism (bradykinesia, diminished pos-
tural reflexes, cogwheel rigidity [right arm], shuf-
fling, short-stepped gait, and decreased spontaneous
eye blink rate). There was no autonomic dysfunction
and eye movements were intact. Dopaminergic treat-
ment had little effect. After 5 years, the patient devel-
oped progressive weakness of the arms and legs with
atrophy, fasciculations, and hyperreflexia. Interest-
ingly, the patient also demonstrated symptoms char-
acteristic of frontotemporal dementia (FTD), such as
loss of interest in social contacts and family, short
attention span, logopenia, verbal apraxia, persevera-
tion, decreased personal hygiene, hyperorality, reck-
less behavior in traffic, sexual disinhibition, and
apathy. Case I-2 and II-4 also appear to have been
affected. However, no medical records were avail-
able. Patient I-2 developed limb weakness at age 70,
leading to paralysis and death within 3 years. Patient
II-4 developed speech impairment at age 60 and also
died within 3 years. Patient II-2 (obligate carrier)
died at age 50 from cardiovascular disease. Detailed
clinical characteristics are provided in table e-2.
Discussion. Several ANG mutations in FALS have
been reported, but clear segregation of mutations
with the disease has not been shown. Here, we report
the K17I mutation segregating with disease in a large
pedigree. The fact that II-2 and a carrier (75 years of
age) were without symptoms of ALS suggests incom-
plete penetrance of the mutation. This might explain
why mutations in this codon have only been found
in SALS. The K17I mutation was previously re-
ported in three cases and K17E in two cases.3,6
This study provides a report of a patient with an
ANG mutation and ALS, FTD, and parkinsonism.
Five percent of patients with ALS also have FTD and
up to 50% demonstrated mild cognitive impairment.
Similarly, relatives of patients with ALS have an in-
creased risk for developing PD. Therefore, genes in-
volved in ALS are also considered candidate genes for
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other neurodegenerative disorders. Indeed, an Italian
study reported a SALS patient with a 132C¡T mu-
tation and frontal lobe dysfunction.4
ANG is highly conserved between species, sug-
gesting it has an important biologic function. Model-
ing of the K17I mutation using PMut predicted this
to be pathogenic. Two functional studies demon-
strated that the K17I mutation results in loss of func-
tion, possibly leading to insufficient ribosomes
synthesis, decreased protein translation, and ulti-
mately decreased motor neuron viability.6,7
We report segregation of the K17I mutation with
FALS and a patient with FALS, FTD, and parkin-
sonism, which possibly implicates ANG in these
diseases.
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Figure Mutation analysis and partial pedigree
(A) Wild type sequence and the K17I mutation. (B) Three-dimensional structure of ANGmodel-
ing the K17I mutation in ball-and-stick representation. The figure was created using the pro-
gram PyMOL (DeLano Scientific). (C) Sequence alignments of ANG in different species.
Sequencesweremultiply aligned usingHomologene (http://www.ncbi.nlm.nih.gov/sites/entrez/
query.fcgi?db homologene). The numbering on top of the alignments correlates with the hu-
man amino acid sequence. Amino acid 17, which is the site of K17I, is indicated in red. (D) A
simplified version of the pedigree is depicted to protect the privacy of the family. A partial
four-generation pedigree is shown. All individuals marked in black have amyotrophic lateral
sclerosis. All individuals carrying the122AT (K17I) mutation aremarked in the pedigree. The
obligate carrier (II-2) died at 50 years of age due to cardiovascular disease. No DNAwas avail-
able from this individual. The spouse of II-2 tested negative for themutation.
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INFLAMMATORY PSEUDOTUMOR ASSOCIATED
WITH HIV, JCV, AND IMMUNE RECONSTITUTION
SYNDROME
A 37-year-old HIV-positive African woman devel-
oped severe chronic diarrhea. Her CD4 T cell
count was 25 cells/mm3. Within 1 month of initia-
tion of highly active antiretroviral therapy (HAART)
her plasma HIV viral load became undetectable and
CD4 T cell count rose to 96 cells/mm3, and con-
tinued to rise over the following months.
Two months after the initiation of HAART she
developed vertigo, loss of balance, incoordination,
slurred speech, and tremor of the neck and limbs.
Neurological examination revealed ocular abnormal-
ities, dysarthria, and monotonic speech. She had bi-
lateral limb dysmetria, past-pointing and endpoint
tremor, impaired heel-knee-shin testing, head tremor,
and a wide based, ataxic gait.
Initial brain MRI revealed a confluent, nonenhanc-
ing area of signal abnormality predominantly involving
the inferior right cerebellar hemisphere and extending
to the posterior vermis, right cerebellar peduncle, and
inferomedial aspect of the left cerebellar hemisphere. Six
months later,MRI revealed progression of the cerebellar
lesion, with nodular enhancement along the inferome-
dial aspect of the right cerebellar hemisphere. The pa-
tient remained clinically stable. MRI 8 months later
revealed a large cystic ring-enhancing lesion in the loca-
tion of the previously noted high signal intensity lesions
of the cerebellum, with compression of the posterior
fourth ventricle (figure, A).
CSF revealed WBC 1, Prot 64, Gluc 49, and neg-
ative cytomegalovirus DNA PCR, Cysticercosis IgG
Ab, Epstein-Barr virus DNA PCR, Venereal Disease
Research Laboratory, and Cryptococcus Ag. Bacte-
rial, viral, and fungal cultures were negative. JCV
PCR was positive. Stereotactic biopsy of the cerebel-
lar lesion, performed 17 months after the onset of
neurologic symptoms, revealed giant cells with pleo-
morphic hyperchromatic nuclei, often multiple, sur-
rounded by a dense infiltrate of lymphocytes and
plasma cells (figure, B). The bizarre, pleomorphic
cells were GFAP positive, demonstrated diffuse nu-
clear reactivity for p53 antigen, a high MIB-1 (Ki-
67) index, and focal, faint reactivity for polyoma
virus T antigen (figure e-1 on the Neurology® Web
site at www.neurology.org). Inflammatory infiltrates
marked both for T and B cells (CD3, CD43, CD20,
CD79a). The adjacent cerebellar folia were atrophic,
with total loss of granular cell neurons, preservation
of Purkinje cells, and infiltrates of lymphocytes and
histiocytes. Four 10-m-thick sections of the mass
were cut and utilized for DNA extraction; PCR was
performed and demonstrated a 173 base pair band
diagnostic of polyoma virus; its identity as JCV was
further confirmed with a BamHI digest which pro-
duces 2 DNA fragments of 120 and 53 base pairs
(JCV, but not BKV or SV40 has this restriction site
in the amplicon)1 (figure, C). A JCV-associated in-
flammatory pseudotumor was diagnosed. The pa-
tient has a stable pancerebellar syndrome 24 months
after onset of neurologic symptoms.
Discussion. The immune reconstitution inflamma-
tory syndrome (IRIS) in HIV-infected patients receiv-
ing HAART is characterized by paradoxical clinical or
radiologic deterioration despite an increasing CD4 T
cell count and decreasing HIV viral load.2 Foreign or-
ganisms become unmasked and trigger a disproportion-
ate immune response.2 IRIS has been reported in
association with JCV infection, the cause of progressive
multifocal leukoencephalopathy (PML).3 The radio-
logic features of PML are generally characterized by fo-
cal high-signal lesions predominantly affecting white
matter structures; in the cerebellum, it has been associ-
ated with atrophy of the folia, with or without white
matter involvement. While PML generally shows mini-
mal contrast enhancement, this is more frequent in
IRIS-associated PML. The radiologic features in the
current patient, demonstrating a cystic lesion with nod-
ular enhancement were unusual, raised the possibility of
a secondary neoplastic or infectious non–JCV-related
lesion, and led to the eventual performance of a brain
biopsy.
PML is histologically characterized by the triad of
oligodendroglial inclusions, demyelination, and bi-
zarre, atypical astrocytes.4 In the cerebellum, selective
loss of granular cell neurons, as seen in the present
case, is common. PML may be associated with vari-
able host inflammatory response. In the case of IRIS-
associated PML, there are appreciable inflammatory
infiltrates, with a preponderance of T cells.4,5 Oligo-
dendroglial nuclei with characteristic viral inclusions
may be rare or absent, and bizarre pleomorphic or
multinucleated cells may have astrocytic or histio-
cytic origins.6 Pathology in the current patient was
unusual, as the combination of dense inflammation
and bizarre glial cells resulted in a pseudotumor for-
mation, heretofore unreported in JCV-associated
IRIS. In our patient, oligodendroglial inclusions
were not evident, although the abnormal morphol-
ogy of giant cells was typical of JCV-transformed as-
trocytes, and the granular cell loss was characteristic
of PML. The juxtaposition of the intense predomi-
nantly lymphoplasmacytic infiltrate surrounding
these transformed cells is likely to represent an IRIS-
induced inflammatory response.7
This JCV-associated pseudotumor is an unusual
manifestation of the spectrum of IRIS neuropatholo-
gies. Given its clinical and radiologic overlap with
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other tumoral and infectious entities, clinicians must
be alert to the differential diagnosis.
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Figure MRI and histologic examination of the cerebellum
(A) Gadolinium-enhanced T1 FLAIR MR image demonstrating a large cystic ring-enhancing
lesion in the context of high signal intensity lesions of the cerebellum. (B) Excisional biopsy
of the cerebellum demonstrating bizarre multinucleated giant cells surrounded by an in-
flammatory cell infiltrate (hematoxylin-eosin, original magnification 100). (C) Ethidium-
bromide stained gel demonstrating presence of JCV in the patient’s pseudotumor.
Formalin-fixed, paraffin-embedded sections of the patient’s lesion (lanes 4 and 7) and
autopsy-derived progressivemultifocal leukoencephalopathy (PML) (lanes 5 and 8) and nor-
mal brain (lanes 3 and 6) were used to extract DNA for PCR. Lanes 2, 3, 4, and 5 show the
results of PCR amplification of a 173 base pair segment of polyoma virus in a reaction run
without template DNA (lane 2), with normal brain DNA (lane 3), DNA from the patient’s lesion
(lane 4), and from an unrelated case of PML (lane 5). Lanes 6, 7, and 8 display BamHI digests
of the PCR products run in lanes 3, 4, and 5, respectively. Both the patient’s lesion and the
case of PML show specific, 120 and 53 base pair fragments that occur only with JCV,
which has a BamHI restriction site in the amplicon (SV40 and BKV do not share this restric-
tion site). Lane 1 contains a 100 bp DNA ladder.
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